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Neither dosage nor serum levels of antiepileptic drugs are predictive for 
efficacy and adverse effects
Introduction
The purpose of this study is to demonstrate the use 
of two measures for therapeutic potency when 
assessing antiepileptic therapy, in particular when 
using multiple drugs (polypharmacy). Furthermore, 
we investigated the correlation between pharmaco­
therapy and quantitative outcome measures using an 
adaptation of scales developed for drug trials by the 
Veteran Affairs Cooperative Study Group [1]. In par­
ticular, we were interested whether either drug dos­
age or serum levels would be the best indicators for 
outcome of treatment
In the 1960s and 1970s, measurement of serum 
levels of antiepileptic drugs (AEDs) was increasingly 
used for monitoring antiepileptic pharmacotherapy. 
Notwithstanding the publication of several mono­
graphs devoted to this topic, it is still controversial 
whether a clear-cut relationship exists between 
serum level and efficacy or serum level and side- 
effects. In particular in polypharmacy, where meta­
bolic interactions may occur, it is important to know 
how serum levels are to be interpreted.
For the measurement of exposure to AEDs in the 
case of polypharmacy, we used the prescribed daily 
dose/defined daily dose (PDD/DDD) ratio, as de­
scribed in previous papers [2-4]. In analogy with the 
PDD/DDD ratio, we propose the use of the observed 
serum level/average therapeutic level (OSL/ATL) ratio 
as a tool for the study of AED efficacy. In order to 
determine the nominator of this ratio, we used the 
therapeutic ranges as published in handbooks and 
other publications.
To assess whether this OSL/ATL ratio can be used 
as a parameter to predict drug effects, we studied 
the data of a population of epileptic patients on 
monopharmacy and polypharmacy. We also used 
indices to obtain quantitative outcome measures for 
the efficacy and for adverse effects of the treatment. 
These indices, which are summarized by the com­
posite index of impairments (Cll), are briefly ex­
plained in the Methods section.
For 100 patients on monopharmacy and 100 on 
polypharmacy we assessed whether the PDD/DDD 
ratio or the OSL/ATL ratio was the better predictor of 
the Cll. The prediction of each of the subindices was 
assessed separately. The correlation between the 
OSL/ATL ratios and the PDD/DDD ratios was also 
examined.
Methods
Population
Patients who were referred to tertiary epilepsy care 
facilities in the Netherlands were studied. The popu­
lation sampled consisted of out-patients from the 
Instituut voor Epilepsiebestrijding in Heemstede, 
from one of the Institute's regional out-patient 
departments in Utrecht, and from the Hans Berger 
Kliniek in Breda. A previous study established that
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Abstract
In order to assess whether doses or serum levels are 
predictive for the efficacy and adverse effects of antiepileptic 
drugs (AEDs), measures for exposure to drug combinations 
have to be used. For doses, the ratio of the observed 
prescribed daily dose (PDD) and the average defined daily 
dose (DDD) considered effective for the main indication of 
the drug was used, in analogy for serum levels, the OSL/ATL 
ratio, he. the ratio of the observed serum level and the 
average therapeutic level was used, In polypharmacy these 
ratios can be summed as they are normalized measures of 
strength. The correlations of these ratios with outcome 
measures were studied in 200 patients attending out-patient 
clinics of special centres for epilepsy; half of these patients 
were treated with monopharmacy and half with 
polypharmacy. As outcome measures the following indices 
were used: the index of seizures, which quantifies seizure 
type and frequency, the seizure activity index, the 
neurotoxicity score, the systemic toxicity score, and the 
composite index of impairments, which is the sum of the 
seizure activity index and the neurotoxicity score and the 
systemic toxicity score. When all data were pooled, the 
correlation coefficient between the PDD/DDD ratio and the 
OSL/ATL ratio was 0.77. However, when the data were 
examined separately for the monopharmacy and 
polypharmacy groups, the correlation was 031 for the 
monopharmacy group and 0.50 for the polypharmacy 
group. Neither the PDD/DDD ratio nor the OSL/ATL ratio 
correlated with the composite index of impairments or with 
any of the individual indices. Factors such as the difficulty of 
titrating the endpoint of seizure suppression and the 
development of tolerance to adverse drug effects may 
perhaps be responsible for these findings. This observational
study signals the problem.
Accepted July 1995.
there are no differences in patient characteristics or 
treatment approach between these three locations
[3]. These patients cover a wide range: at one end 
patients are well controlled by AEDs but are under 
treatment for psychosocial problems; at the other 
end patients are resistant to present-day AEDs. 
Therefore this cohort is particularly suited for com­
parative studies on correlations of therapy and out­
come.
If the patients met the selection criteria, they were 
asked to participate in the study, which was linked 
with their regular visit to their attending physician. 
For the present study the data of the first 100 
patients who were treated with monopharmacy and 
the first 100 patients who were treated with poly­
pharmacy were examined. Of these 200 patients, 
60 patients visited their attending physician twice 
within the time span of the intake period, and on 
both occasions blood samples were taken. The data 
from patients who had a change in drug dosage 
(n ~ 35) were analysed separately to determine 
whether or not a correlation existed in individual 
patients between either the PDD/DDD ratio or the 
OSL/ATL ratio and the clinimetric indices. The study 
was approved by the Ethics Committees of both 
Institutes.
Table 1 Defined doily dose (ODD) and average
therapeutic tevei (ATI) per antiepileptic 
drug
Selection criteria
Patients who visited an adult out-patient epilepsy 
clinic were included. These patients suffered from 
well-defined types of seizures according to the Inter­
national Classification of the International League 
Against Epilepsy.
Patients with factors that were believed to compli­
cate the evaluation process, such as progressive brain 
disorders, obvious non-compliance with drug usage 
or seizure registration, pseudo-seizures and severe 
mental retardation, were excluded from the study. 
Patients who were treated with vigabatrin were also 
excluded as the mechanism of action of this drug is 
typically independent of steady-state serum levels.
Analysis of drug treatment and dosage
In order to compare the effect of one drug with the 
effect of a combination of several other drugs, it is 
necessary to find a measure of equipotency. To this 
end, all daily dosages were standardized using the 
PDD/DDD ratio. The PDD is the dose prescribed by 
the physician for the individual patient, and as only 
compliant patients were admitted to the study, the 
PDD equals the observed daily dose. The DDD is the 
assumed average effective dose per day for the drug 
used in its main indication in adults. The DDD is 
expressed in terms of the amount of the active sub­
stance. DDD values are assigned by the WHO Col­
laborating Centre for Drugs Statistics Methodology 
and the Nordic Council on Medicines, which regular­
ly publish "Guidelines for Defined Daily Doses'7. This 
publication is based on dose-documents per drug as 
prepared by WHO Oslo, based on international text­
books, journals and documentation approved by 
drug control authorities. The dose-documentations 
are available on request from the WHO Collaborating
Centre, Oslo [5]. The published DDDs of AEDs are 
presented in Table 1.
The rationale of adding up the PDD/DDD ratios of 
different AEDs is based upon the definition of DDD
Antiepileptic drug DDD (mg) [5] ATL fag/ml) [6-12]
Carbamazepine 1000 7
Clobazam 20 0.35
Clonazepam 8 0.04
Ethosuximide 1250 70
Oxcarbazepine 1000 22
Phénobarbital 100 30
Phenytoin 300 15
Valproate 1500 70
as the maintenance dose of that particular drug for 
the main indication in adults. According to the WHO 
Defined Daily Dose Model, half a DDD of AED-I plus 
half a DDD of AED-II should be as effective as a full 
dose of either of them. For example, 750 mg valpro­
ate plus 500 mg carbamazepine should be as effec­
tive as 1500 mg of valproate or as 1000 mg of carbam­
azepine. For combinations it may ultimately appear 
that the PDD/DDD ratio for a particular combination, 
which is the "average effective dose per day for the 
drug-combination used in its main indication in 
adults" may be less than unity (supra-additive effect) 
or greater than unity (infra-additive effect), However, 
we are not concerned with efficacy itself, but with 
comparison of the PDD/DDD ratio and the OSL/ATL 
ratio as a parameter for therapeutic potency.
Analysis of serum levels
In analogy to the ratio for drug dosage, we con­
structed a ratio for the serum levels of the AEDs, the 
OSL/ATL ratio. The ATL (average therapeutic level) 
was assessed by averaging data from papers pub­
lished on this issue [6-12]. These papers often pre­
sent a therapeutic range. We used the serum levels 
of seizure-free patients on monotherapy. If a range 
was published, the average of the minimum and 
maximum value was taken. We assume that, given 
the present AEDs, patients seizure-free on drug A at 
an average therapeutic serum level should also be 
well controlled by drug B when its average thera­
peutic serum level is reached. The ATL for each drug 
used in this study is shown in Table 1. The OSL 
(observed serum level) is the serum level found for 
each AED prescribed to the patient. As was done for 
the PDD/DDD ratio, the OSL/ATL ratios were 
summed when the patients were treated with poly­
pharmacy.
Analysis of treatment outcome
For the analysis of treatment outcome, we used the 
index of seizures, the seizure activity index, the 
neurotoxicity score, and the systemic toxicity score, 
which are combined to form the composite index of 
impairments (Cll). The Cll is derived from the com­
posite index used in the Veterans Affairs study of the 
efficacy and toxicity of AEDs [1] and has been vali­
dated in a study by Wijsman et al. [13].
The index of seizures is a rating scale which con­
siders seizure frequency as well as seizure type. The 
index may be modified by factors which are con­
sidered to influence seizure severity, such as the 
presence of an aura, avoidable provocative factors, 
seizures during sleep only, clustering of seizures, and 
the duration of impairment after the seizure. This 
modified index of seizures results in the seizure ac­
tivity index. We used a neurotoxicity score and a sys­
temic toxicity score to quantify the toxicity of a 
medication. The score ranges are graded according 
to the severity of the toxicity.
The Cll denotes the total of the impairments due 
to the disorder, as it considers both the seizure ac­
tivity index, the neurotoxicity score and the systemic 
toxicity score, which are summed. The outcome of 
treatment, as reflected by the Cll score, was classified 
Into four groups [13]:
1 Cll = 0: optimal epilepsy control;
2 Cll = 1-10: acceptable but suboptimal epilepsy
control;
3 Cll = 11-49: fair-to-poor but not an unacceptable 
epilepsy control;
4 Cll > 50: unacceptable epilepsy control.
Blood sampling
After we obtained the patient's consent, blood 
samples were taken for monitoring clinical chemistry, 
such as electrolytes, liver and kidney function, 
haematological evaluation of toxicity (idiosyncratic 
reactions, allergies), and therapeutic drug moni­
toring, i.e. to measure drug concentration in steady- 
state conditions, to identify individual pharmaco­
kinetics, to anticipate individual variations in drug 
utilization and drug-drug interactions, and to ident­
ify non-compliance.
Blood sampling was omitted if data for previous 
blood samples were available and representative for 
the patient's current clinical state, provided no treat­
ment changes or other destabilizing events occurred 
during the interval and provided the interval did not 
exceed 12 months. Measurements were performed 
by routine methods for therapeutic drug monitoring 
(high-pressure liquid chromatography) [12]. When 
blood sampling was repeated, blood sampling for 
each individual patient was always at the same time 
of the day.
Patient data collection
After the visit to the clinician, the patients were inter­
viewed and examined by the investigator in order to
obtain data necessary for the determination of the 
indices without prior knowledge of the treatment 
dose or serum levels. Subsequently, the patient's file 
was handed to the investigator in order to complete 
the research file. Patient seizure charts of past year(s) 
were studied in order to determine fluctuations in 
seizure frequency since the last treatment change. 
The medication and doses prescribed as well as the 
corresponding serum levels were noted. This allowed 
for the assessment of the PDD/DDD ratio and the 
OSL/ATL ratio per individual drug.
Statistical analysis
The x2 test was used to analyse possible differences 
in population characteristics of the group on mono­
pharmacy and polypharmacy. Spearman's corre­
lation coefficient was used to analyse correlations. A 
correlation was considered good when the corre­
lation coefficient was at least 0.70.
Results
Population characteristics
103 men and 97 women participated in the study. 
The mean age was 39, The age of seizure onset did 
not differ significantly between patients on mono­
pharmacy and patients on polypharmacy, although 
more patients on polypharmacy had had seizures 
since infancy. 151 patients had partial seizures and 
49 generalized seizures. In the group treated with 
monopharmacy more patients had generalized seiz­
ures than in the group treated with polypharmacy, 
29 and 20, respectively.
Treatment
Carbamazepine was prescribed most frequently for 
patients on monopharmacy, he. for 48 patients, 
followed by valproate (35 patients). The other AEDs 
used in monopharmacy were phenytoin (9 patients), 
oxcarbazepine (5 patients), and phenobarbital (3 
patients). Carbamazepine was also the most fre­
quently prescribed AED for patients on polyphar­
macy, i.e. for 86 patients, followed by valproate 
(55 patients). For patients on polypharmacy, the 
mean number of AED per patient was 2.5: 60 
patients were prescribed 2 AEDs, 38 patients 3 AEDs, 
and 2 patients 4 AEDs.
Table 2 Median prescribed daily dose/defined daily dose (PDD/DDD) ratios for individual antiepileptic
drugs
Drug
Carbamazepine
Clobazam
Clonazepam
Ethosuximide
me
Phenobarbital
Valproate
Monopharmacy
median PDD/DDD ratio (range)
0.7 (0.1-2.0)
0.6 (0.4-0,9) 
0.8 (0.5-1.0) 
1.1 (0.64.3)
0.8(0.2-13)
n
48
5
3
9
35
Polypharmacy
0.9 (0.2-2.0) 
0.7 (0.5-2,0) 
0.13 (0.13) 
0.6 (0.2-1.2) 
1.3 (0.6-2.0) 
0.7 (0.1 -2.1) 
1.1 (0.5-2.Q) 
1.0 (0.4-2.3)
median PDD/DDD ratio (range) h
86
13
5
12
2
21
47
55
Table 3 Median observed serum level/average therapeutic levei (OSL/ATL) ratios for individual
antiepileptic drugs
Drug Monopharmacy Polypharmacy
median OSL/ATL ratio (range)
Carbamazepine
Clobazam
Clonazepam
Ethosuximide
Oxcarbazepine
Phénobarbital
Phenytoin
Valproate
0.92 (0.24-1.44)
0.54 (0.30-0.85) 
0.59 (0.17-0.99)
0.79 (0.19-1.49)
0.97 (0.50-1.76)
n median OSL/ATL ration (range) n
48 0.89 (0.29-1.67) 86
— 1.08 (0.23-2.71) 13
— 1.44 (0.43-2.50) 5
0.63 (0.21-1.37) 12
5 0.17(0.13-0.20) 2
3 0.56(0.04-1.21) 21
9 0.88 (0.31-1.67) 47
35 0.89 (0.23-1,71) 55
Prescribed daily dose/defined daily dose ratio 
For all drugs used in the group of patients on mono­
pharmacy, the median PDD/DDD ratio was 0.7 
(range 0.1 -2.0; Table 2) and the mean PDD/DDD 
ratio was 0.8. In the group on polypharmacy, the 
median sum of all PDD/DDD ratios per prescription 
was 2.1 (range 0.7-5.2). The mean of these summed 
PDD/DDD ratios was 2.2. In the polypharmacy 
group, the median PDD/DDD ratio for the individual 
AED in the composite prescriptions was higher than 
the median PDD/DDD ratio of these drugs when pre­
scribed alone, with the exception of phenobarbital 
(Table 2).
Observed serum level/average therapeutic level 
ratio
The median OSL/ATL ratio for the patients on mono­
pharmacy was 0.90 (range 0.17-1.76), as was the 
mean OSL/ATL ratio, and for the patients on poly­
pharmacy the median of the sums of OSL/ATL ratios 
of the component drugs was 2.00 (range 0.83-4.50), 
with a mean sum of OSL/ATL ratios of 2.10.
The median OSL/ATL ratio for the individual AED Discussion
groups. The correlation between these two ratios 
was better for the patient group on polypharmacy 
than for the patient group on monopharmacy (corre­
lation coefficients of 0.50 and 0.31, respectively).
When looking at the whole population (n = 200), 
for the PDD/DDD ratio as well as for the OSL/ATL 
ratio, the correlation with the clinimetric indices was 
marginal, although it was slightly better for the 
PDD/DDD ratio than for the OSL/ATL ratio, but this 
difference was not significant (p > 0.05) (Table 4). For 
the group on polypharmacy, the correlations of both 
ratios with the clinimetric indices were slightly better 
than for the group on monopharmacy, but again this 
difference did not reach statistical significance 
(p > 0.05) (Table 4).
There was no correlation between the two ratios at 
different times and doses, and the corresponding 
clinimetric indices of the 35 patients who had had a 
change of dosage during the observation period and 
who were assessed individually.
measured in the serum of patients on polypharmacy 
was lower than the median OSL/ATL ratio for the 
same drug when the patients were treated with 
monopharmacy, with the exception of phenytoin 
(Table 3). The median PDD/DDD ratio per drug 
increased when the number of drugs per patient 
increased; however, the OSL/ATL ratio per drug 
decreased.
Correlation between study parameters
There was a good correlation between the PDD/DDD 
ratio and the OSL/ATL ratio if all patients were con­
sidered (correlation coefficient 077). The correlation 
decreased when this correlation was tested separ­
ately for the polypharmacy and the monopharmacy
The use of polypharmacy makes it difficult to comp­
are the strength of the medications prescribed to a 
patient at different times or between patients. The 
ratio of the prescribed daily dose to the defined daily 
dose is an internationally recognized tool to make 
such comparisons possible. The WHO Collaborating 
Centre for Drugs Statistics Methodology and the 
Nordic Council on Medicines in Oslo regularly assess 
and publish the defined daily doses. In monophar­
macy, the serum level of the administered drug is 
assumed to provide a better Indication of the active 
amount of drug aimed at the target than the dose 
itself. In polypharmacy, this relationship has never 
been studied. We proposed to use the ratio of the 
observed serum level over the average 'therapeutic'
Table 4 Correlation coefficients of the prescribed daily dose/defined daily dose (PDD/DDD)
ratios and the observed serum level/average therapeutic level (OSL/ATL) ratios with the 
dinimetric indices
Clinimetric index
Index of seizure 
Seizure activity index 
Neurotoxicity score 
Systemic toxicity score 
Composite index of impairments
Overoil
f  p < 0.05. 
$ p > 0.05,
PDD/DDD OSL/ATL
0,24$ 
0.211 
0.40t 
0,01t 
0.311
* Summed ratios per prescription.
0.23t
0.20t
0.34$
0.01$
0.28f
Monopharmacy Polypharmacy
PDD/DDD OSL/ATL PDD/DDD OSL/ATL
0.26t 0.15$ 0,15$ 0.22f
0.26$ 0.18* 0,16$ 0.20f
- 0.0 7$ 0,06$ 0.27$ 0.15$
- 0.03$ -0.15$ - 0.18$ -0.16$
0.13$ 0.07$ 0.18$ 0.17$
level (OSL/ATL) as parameter. This parameter Is a polypharmacy the median PDD/DDD ratio of an in­
normalized measure of the strength of the levels dividual drug increased, the median OSL/ATL ratio of 
found and these can therefore be summed as long as an individual drugs decreased, reflecting metabolic 
they concern drugs given for the same purpose. It interaction.
might be argued that polypharmacy should be The correlation of the PDD/DDD ratio with the
outcome measures for seizures and toxicity were 
both poor. Better correlations were seen between 
the PDD/DDD ratio with the clinimetric indices and
avoided and that it is an academic exercise to study 
polypharmacy. Indeed, while Guelen et ai. still report 
an average use of 3.2 AEDs per patient [14], we 
found an average number of AEDs prescribed per 
patient of 1.7. This- reflects a tendency to prefer 
monopharmacy over polypharmacy, However, 
polypharmacy is certainly not being phased out, 
because as recently as the 20th International Epilepsy 
Congress, which was held in July 1993 in Oslo, a 
satellite symposium was devoted to rational poly­
pharmacy in the treatment of epilepsy.
In our study the median PDD/DDD ratio per drug 
was lower for patients on monopharmacy (0.8) than 
the median sum of PDD/DDD ratios for patients on 
polypharmacy (2.2). Comparison of the median 
PDD/DDD ratio in monopharmacy and the median 
PDD/DDD ratio for the same individual drugs applied 
in composite prescriptions (polypharmacy) showed 
that this value was always slightly higher in polyphar­
macy, notwithstanding the fact that in many cases 
several drugs were used simultaneously (Table 2). 
The only exception was phenobarbital.
In polypharmacy, the PDD/DDD ratios for the in­
dividual drugs were close to unity. The median 
PDD/DDD ratios for clonazepam and ethosuximide 
were, however, appreciably lower than unity. It is 
possible that the daily dosages advised by the WHO 
Collaborating Centre for Drug Statistics for these 
AEDs are too high. This is quite likely in the case of 
clonazepam, as the median OSL/ATL ratio was high 
(1.44). However, this is not the case for ethosuxi- 
mide, which had very similar median PDD/DDD and 
median OSL/ATL ratios (0.57 and 0.63). While in
between the OSL/ATL ratio with the clinimetric in­
dices with polypharmacy than with monopharmacy. 
However the difference was not statistically signifi­
cant The lack of correlation meant that we could not 
study possible supra-additive or infra-additive effects 
of polypharmacy. Even when two sets of data per 
patient were available, no statistical significance was 
found when we assessed the correlation within 
patients between the PDD/DDD ratio, the OSL/ATL 
ratio and the clinimetric indices.
The results of this study support the assertion that 
a difference in dosage or serum levels of AEDs does 
not predict a difference in either efficacy or adverse 
effects of these drugs. The reasons can only be 
guessed at. As far as the OSL/ATL is concerned, there 
may be a biochemical reason as not all metabolites 
have yet been identified and nothing is known about 
their intrinsic activity on efficacy and adverse effects. 
For this reason it was also not possible to incorporate 
an OSL/ATL ratio for known metabolites in our 
equation. Another plausible reason for the disap­
pointing results is that the paroxysmal character of 
the seizures makes it difficult to accurately titrate the 
endpoint 'freedom from seizures'. The dose may well 
have been higher than necessary in those patients
who were seizure-free.
With respect to the outcome measures of drug 
toxicity, the occurrence of tolerance to adverse 
effects may interfere with the expected relation 
between the PDD/DDD or OSL/ATL and the neuro-
*
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toxicity score and the systemic toxicity score. As this 
was an observational study, the material does not 
permit an answer to these questions, it can only sig­
nal the problem.
Acknowledgements
The authors wish to thank M. Engelsman, A. van 
Wieringen, G. Brekelmans, S. de Froe and D.J.P. 
Wijsman for their participation in this study, and Mrs. 
A.M. Harting for assistance in the preparation of the
manuscript.
This study was supported by the Commissie 
Landelijk Epilepsie Onderzoek (CLEO-NEF), Grant 
No. A-81.
References
1 Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, 
Collins JF. A method of quantification for the evaluation of 
antiepileptic drug therapy. Neurology 1983;33(Suppl 1):26- 
37.
2 Wijsman DJP, Lammers MW, Hekster YA, Keyser A, Renier 
WO, Meinardi H, et al. Epilepsy treatment in The Nether­
lands. Comparison of two medical centres. Acta Neurol 
Scand 1993;87:438-42.
3 Lammers MW, Hekster YA, Keyser A, Renier WO, Meinardi 
H, van Lier H, et al. Epilepsy treatment In The Netherlands. 
Comparison of matched groups of two medical centres. 
Acta Neurol Scand 1994;89:415-20.
4 Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier 
WO, van Lier H, et al. Clinimetric analysis of treatment 
objectives and clinical status. Individualised treatment in epi­
leptic patients. Epilepsia 1994;35:1271-8.
5 Guidelines for DDD. Oslo: WHO Collaborating Centre for 
Drugs Statistics Methodology and Nordic Council on 
Medicines, 1993.
6 Schobben AFAM. Pharmacokinetics and therapeutics in epi­
lepsy [dissertation]. Nijmegen: University of Nijmegen, 
1979.
7 Pippenger CE. Rationale and clinical application of thera­
peutic drug monitoring. Pediatr Clin North Am 1980;27(4): 
891-925.
8 Froscher W, Eichelbaum M, Cugler R, Hildenbrand G, Penin 
H. A prospective randomised trial on the effect of moni­
toring plasma anticonvulsant levels in epilepsy. J Neurol 
1981;224:193-201.
9 Eadie MJ. Anticonvulsant drugs. An update. Drugs 1984;27: 
328-63.
10 Keyser A, Hekster Y, Schaap M, Termond E. Antiepileptic 
drug therapy in outpatients. J Pharmacoepidemiol 1990;1: 
35-47.
11 Larkin JG, Herrick AL, McGuire GM, Percy-Robb IW, Brodie 
Mj. Antiepileptic drug monitoring at the epilepsy clinic, 
a prospective evaluation. Epilepsia 1991;32:89-95.
12 Meijer JWA. Knowledge, attitude and practice in antiepilep­
tic drug monitoring, Acta Neurol Scand 1991 ;83(Suppl 
134):1-128.
13 Wijsman DJP, Hekster YA, Keyser A, Renier WO, Meinardi H. 
Clinimetrics and epilepsy care. Pharm Weekbl Sci 1991;13* 
182-8.
14 Guelen PJM, van der Kleijn E, Woudstra U. Statistical analysis 
of pharmacokinetic parameters in epileptic patients chroni­
cally treated with anti-epileptic drugs. In: Schneider H, Janz 
D, Gardner-Thorpe C, Meinardi H, Sherwin AL, editors. 
Clinical pharmacology of anti-epileptic drugs. Berlin* 
Springer-Verlag, 1975:2-10.
